GALNTL5

Across TCGA pan-cancer cohorts, GALNTL5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GALNTL5 data layer compared with 18 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GALNTL5 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated GALNTL5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, BLCA, and ESCA are the cancer types where GALNTL5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	1.000	0.528	.016	24	view →
BLCA	OS	Median	IV	0.082	0.590	<.001	18	view →
ESCA	DFS	Median	All	0.080	0.533	<.001	18	view →
LGG	OS	Median	All	0.034	0.909	<.001	12	view →
SKCM	DFS	Median	II,III,IV	0.412	0.209	.013	7	view →
COAD	OS	Median	III,IV	0.168	0.691	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GALNTL5–UCEC (DFS)

Open the UCEC breakdown →